会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Pyrazolopyrimidines
    • 吡唑并嘧啶
    • US07405220B2
    • 2008-07-29
    • US11136023
    • 2005-05-24
    • Qingjie DingNan JiangJohn Lawson Roberts
    • Qingjie DingNan JiangJohn Lawson Roberts
    • C07D239/70A61K31/4162
    • C07D487/04
    • Novel pyrazolopyrimidines of formula (I): are discussed. These pyrazolopyrimidines are capable of inhibiting the activity of cyclin-dependent kinases, most particularly cyclin-dependent kinase 1 (Cdk1), cyclin-dependent kinase 2 (Cdk2), and cyclin-dependent kinase 4 (Cdk4) and are thus useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also provides pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.
    • 讨论式(I)的新型吡唑并嘧啶:。 这些吡唑并嘧啶能够抑制细胞周期蛋白依赖性激酶的活性,特别是细胞周期蛋白依赖性激酶1(Cdk1),细胞周期蛋白依赖性激酶2(Cdk2)和细胞周期蛋白依赖性激酶4(Cdk4)的活性,因此尤其有用 ,治疗或控制癌症,特别是实体瘤。 本发明还提供含有这些化合物的药物组合物以及治疗或控制癌症的方法,特别是治疗或控制乳腺癌,肺癌,结肠癌和前列腺肿瘤的方法。